Claims

1. A method for the manufacture of a fast dissolve tablet that includes:
   a) blending of highly-compactable filler in combination with a highly water-absorbing material and;
   b) adding purified water to the mixture of highly compactable filler and highly water-absorbing material until granules are formed by visual inspection thus creating the cushioning component; and
   c) the cushioning component is milled to a particle size of between 10-325 mesh (2000 – 45 micron); and
   d) adding active-loaded beads to the milled cushioning component to create a mixture followed by an optional step of extrusion and spheronization and the option of including inactive ingredients to improve patient compliance, functionality or manufacturability; and
   e) freeze-drying of the mixture of active-loaded beads and milled cushioning component with or without said extrusion and spheronization to create the Cushioning Beads™; and
   f) compressing the Cushioning Beads™ into a fast dissolve tablet for treatment of a patient in need of said treatment.

2. A method for the manufacture of a fast dissolve tablet that includes:
   a) blending of Avicel® PH101 and Ac-Di-Sol® and;
   b) adding purified water to the mixture of Avicel® PH101 and Ac-Di-Sol® until granules are formed by visual inspection thus creating the cushioning component and;
   c) the cushioning component is milled to a particle size of between 10-325 mesh (2000 – 45 micron); and
   d) adding of active-loaded beads to the milled cushioning component to create a mixture followed by an optional step of extrusion and spheronization and the option of including inactive ingredients to improve patient compliance, functionality or manufacturability; and

e) freeze-drying of the mixture of active-loaded beads and milled cushioning component with or without said extrusion and spheronization to create the Cushioning Beads™; and

f) compressing the Cushioning Beads™ into a fast dissolve tablet for treatment of a patient in need of said treatment.

3. A method for the manufacture of a fast dissolve tablet that includes:

a) blending of Avicel® PH101 and Ac-Di-Sol® in a ratio that the mixture will have Ac-Di-Sol ranging from 5 to 90% by weight and;

b) adding of purified water to the mixture of Avicel® PH101 and Ac-Di-Sol® until granules are formed by visual inspection thus creating the cushioning component and;

c) the cushioning component is milled to a particle size of between 10-325 mesh (2000 – 45 micron); and

d) adding of active-loaded beads to the milled cushioning component to create a mixture followed by an optional step of extrusion and spheronization and the option of including inactive ingredients to improve patient compliance, functionality or manufacturability; and

e) freeze-drying of the mixture of active-loaded beads and the milled cushioning component with or without said extrusion and spheronization to create the Cushioning Beads™; and

f) compressing the Cushioning Beads™ into a fast dissolve tablet for treatment of a patient in need of said treatment.

4. A method for the manufacture of a fast dissolve tablet that includes:

a) blending of a highly-compactable filler in combination with a highly water-absorbing material and;

b) adding of purified water to the mixture of highly-compactable filler and highly water-absorbing material until granules are formed by visual inspection thus creating the cushioning component and;

c) the cushioning component is milled to a particle size of between 10-325 mesh (2000 – 45 micron); and

d) adding of active-loaded beads to the milled cushioning component to create a mixture followed by an optional step of extrusion and spheronization and the option of including nonactive ingredients to improve patient compliance, functionality or manufacturability; and

e) freeze-drying of the mixture of active-loaded beads and the milled cushioning component with or without said extrusion and spheronization until a LOD of 2-15% is achieved to create the Cushioning Beads™ followed by an optional step of extrusion and spheronization of the Cushioning Beads™; and

f) compressing the Cushioning Beads™ into a fast dissolve tablet for treatment of a patient in need of said treatment.

5. A method for the manufacture of a fast dissolve tablet that includes:

a) blending of Avicel® PH101 and Ac-Di-Sol® and;

b) adding purified water to the mixture of Avicel® PH101 and Ac-Di-Sol® until granules are formed by visual inspection thus creating the cushioning component and;

c) the cushioning component is milled to a particle size of between 10-325 mesh (2000 – 45 micron); and

d) adding of active-loaded beads to the milled cushioning component to create a mixture followed by an optional step of extrusion and spheronization and the option of including inactive ingredients to improve patient compliance, functionality or manufacturability; and

e) freeze-drying of the mixture of active-loaded beads and milled cushioning component with or without said extrusion and spheronization until a LOD of 2-15% is achieved to create the Cushioning Beads™; and

f) compressing the Cushioning Beads™ into a fast tablet for treatment of a patient in need of said treatment.

6. A method for the manufacture of a fast dissolve tablet that includes:

a) blending of Avicel® PH101 and Ac-Di-Sol® in a ratio that the mixture will have Ac-Di-Sol ranging from 5 to 90% by weight;

b) adding of purified water to the mixture of Avicel® PH101 and Ac-Di-Sol® until granules are formed by visual inspection thus creating the cushioning component and;

c) the cushioning component is milled to a particle size of between 10-325 mesh (2000 – 45 micron); and

d) adding of active-loaded beads to the milled cushioning component to create a mixture followed by an optional step of extrusion and spheronization and the option of including inactive ingredients to improve patient compliance, functionality or manufacturability; and

e) freeze-drying of the mixture of active-loaded beads and milled cushioning component with or without said extrusion and spheronization until a LOD of 2-15% is achieved to create the Cushioning Beads™; and

f) compressing the Cushioning Beads™ into a fast dissolve tablet for treatment of a patient in need of said treatment.

7. A method for the manufacture of a fast dissolve tablet that includes:

a) blending of a highly-compactable filler in combination with a highly water-absorbing material and;

b) adding purified water to the mixture of highly-compactable filler and highly water-absorbing material until granules are formed by visual inspection thus creating the cushioning component and;

c) the cushioning component is milled to a particle size of between 10-325 mesh (2000 – 45 micron); and

d) adding more than one type of active-loaded beads to the milled cushioning component to create a mixture followed by an optional step of extrusion and spheronization and the option of including inactive ingredients to improve patient compliance, functionality or manufacturability; and

e) freeze-drying of the mixture of active-loaded beads and milled cushioning component with or without said extrusion and spheronization to create the Cushioning Beads™; and

f) compressing the Cushioning Beads™ into a fast dissolve tablet for treatment of a patient in need of said treatment.

8. A method for the manufacture of a fast dissolve tablet that includes:

a) blending of Avicel® PH101 and Ac-Di-Sol® and;

b) adding purified water to the mixture of Avicel® PH101 and Ac-Di-Sol® until granules are formed by visual inspection thus creating the cushioning component and;

c) the cushioning component is milled to a particle size of between 10-325 mesh (2000 – 45 micron); and

d) adding of more than one type of active-loaded beads to the milled cushioning component to create a mixture followed by an optional step of extrusion and spheronization and the option of including inactive ingredients to improve patient compliance, functionality or manufacturability; and

e) freeze-drying of the mixture of active-loaded beads and milled cushioning component with or without said extrusion and spheronization to create the Cushioning Beads™; and

f) compressing the Cushioning Beads™ into a fast dissolve tablet for treatment of a patient in need of said treatment.

9. A method for the manufacture of a fast dissolve tablet that includes:

a) blending of Avicel® PH101 and Ac-Di-Sol® in a ratio that the mixture will have Ac-Di-Sol ranging from 5 to 90% by weight and;

b) adding of purified water to the mixture of Avicel® PH101 and Ac-Di-Sol® until granules are formed by visual inspection thus creating the cushioning component and;

c) the cushioning component is milled to a particle size of between 10-325 mesh (2000 – 45 micron); and

d) adding of more than one type of active-loaded beads to the milled cushioning component to create a mixture followed by an optional step of extrusion and spheronization and the option of including inactive

ingredients to improve patient compliance, functionality or manufacturability; and

e) freeze-drying of the mixture of active-loaded beads and the milled cushioning component with or without said extrusion and spheronization to create the Cushioning Beads™; and

f) compressing the Cushioning Beads™ into a fast dissolve tablet for treatment of a patient in need of said treatment.

10. A method for the manufacture of a fast dissolve tablet that includes:

a) blending of a highly-compactable filler in combination with a highly water-absorbing material and;

b) adding of purified water to the mixture of highly-compactable filler and highly water-absorbing material until granules are formed by visual inspection thus creating the cushioning component and;

c) the cushioning component is milled to a particle size of between 10-325 mesh (2000 – 45 micron); and

d) adding of more than one type of active-loaded beads to the milled cushioning component to create a mixture followed by an optional step of extrusion and spheronization and the option of including inactive ingredients to improve patient compliance, functionality or manufacturability; and

e) freeze-drying of the mixture of active-loaded beads and the milled cushioning component with or without said extrusion and spheronization until a LOD of 2-15% is achieved to create the Cushioning Beads™; and

f) compressing the Cushioning Beads™ into a fast dissolve tablet for treatment of a patient in need of said treatment.

11. A method for the of manufacture of a fast dissolve tablet that includes:

a) blending of Avicel® PH101 and Ac-Di-Sol® and;

b) adding purified water to the mixture of Avicel® PH101 and Ac-Di-Sol® until granules are formed by visual inspection thus creating the cushioning component and;

c) the cushioning component is milled to a particle size of between 10-325 mesh (2000 – 45 micron); and

d) adding of more than one type of active-loaded beads to the milled cushioning component to create a mixture followed by an optional step of extrusion and spheronization and the option of including inactive ingredients to improve patient compliance, functionality or manufacturability; and

e) freeze-drying of the mixture of active-loaded beads and milled cushioning component with or without said extrusion and spheronization until a LOD of 2-15% is achieved to create the Cushioning Beads™; and

f) and compressing the Cushioning Beads™ into a fast dissolve tablet for treatment of a patient in need of said treatment.

12. A method for the manufacture of a fast dissolve tablet that includes:

a) blending of Avicel® PH101 and Ac-Di-Sol® in a ratio that the mixture will have Ac-Di-Sol ranging from 5 to 90% by weight and;

b) adding of purified water to the mixture of Avicel® PH101 and Ac-Di-Sol® until granules are formed by visual inspection thus creating the cushioning component and;

c) the cushioning component is milled to a particle size of between 10-325 mesh (2000 – 45 micron); and

d) adding of more than one type of active-loaded beads to the milled cushioning component to create a mixture followed by an optional step of extrusion and spheronization and the option of including inactive ingredients to improve patient compliance, functionality or manufacturability; and

e) freeze-drying of the mixture of active-loaded beads and milled cushioning component with or without said extrusion and spheronization until a LOD of 2-15% is achieved to create the Cushioning Beads™; and

f) compressing the Cushioning Beads™ into a fast dissolve tablet for treatment of a patient in need of said treatment.